Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017;376(22):2134–46. https://www.ncbi.nlm.nih.gov/pubmed/28564569
Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373(27):2599–607. https://www.ncbi.nlm.nih.gov/pubmed/26571066
Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373(27):2608–17. https://www.ncbi.nlm.nih.gov/pubmed/26575258
Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (June 2020). Melbourne: Gastroenterological Society of Australia; 2020. https://www.gesa.org.au/resources/hepatitis-c-treatment/
Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, et al. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis. Adv Ther 2020;37(9):4033-42. https://www.ncbi.nlm.nih.gov/pubmed/32754824
Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017;66(2):389–97. https://www.ncbi.nlm.nih.gov/pubmed/28128852
Poordad F, Pol S, Asatryan A, Buti M, Shaw DR, Hezode C, et al. MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure [conference abstract 422]. In: Digestive Disease Week 6-9 May 2017, Chicago, Illinois. Gastroenterology 2015;152(5 (Suppl. 1)):S1057. https://www.gastrojournal.org/issue/S0016-5085(17)X5200-1
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378(4):354–69. https://www.ncbi.nlm.nih.gov/pubmed/29365309
Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M, et al. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naive Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol 2020;18(11):2544-53 e6. https://www.ncbi.nlm.nih.gov/pubmed/32621971
